
New hair loss drugs: PP405, pyrilutamide and clascoterone
PP405, pyrilutamide and clascoterone keep coming up on Reddit, TikTok, Instagram and X. None of them is approved for hair loss. Here's what the studies actually show, how to read hair loss and hair transplant content on social media, and why you shouldn't buy these drugs online.
Why are new hair loss drugs popping up all over Reddit, TikTok and Instagram?
Because they promise something finasteride and minoxidil don't: more hair without a tablet that affects hormones throughout the body, or hair follicles that wake up again after lying dormant for years. Names like PP405, pyrilutamide and clascoterone keep cropping up in Reddit threads, in short videos on TikTok, Instagram and YouTube, in discussions on X and in Facebook groups. Some people pass it on to friends on Snapchat. Many wonder whether there's anything in it, which is why we're writing about them.
The most important point first. None of the drugs in this article is approved for hair loss in Norway, the EU or the USA as of October 2026. Several of the figures shared online come from the companies themselves and have not been assessed by other researchers. We don't recommend any of them, and we don't sell any of them. This article describes a trend and what the research actually shows, so you can watch the next video with a slightly more critical eye.
Are any of the new hair loss drugs approved?
No. As of October 2026, none of them is approved for hair loss by the medicines regulators in Norway, the EU or the USA. The table shows how far each has come, as we found it in the companies' own announcements, in trial registries and in published studies.
| Drug | Status October 2026 | Approved |
|---|---|---|
| Clascoterone 5% | Two phase 3 studies completed, US application planned for early 2027 | No |
| Pyrilutamide (KX-826) | Phase 3 in China met its goal in 2026, an earlier phase 3 did not | No |
| PP405 | Large phase 2/3 study started in October 2026 | No |
| GT20029 | Phase 2 published, phase 3 is the next step according to the company | No |
| RU58841 | Never fully developed, sold online as a "research chemical" | No |
| Verteporfin | Animal studies, no published studies in hair transplantation | No |
| Hair cloning | Hair follicles formed in skin on mice, no published results in humans | No |
"Approved" here means a medicines regulator has assessed the drug and said yes specifically to its use for hair loss. A substance existing, or being approved for something else, is not the same thing.
Clascoterone: what is it, and how far has it got?
What it is. Clascoterone is an antiandrogen applied to the skin. It competes with the hormone DHT for the same receptor in the hair follicle, the androgen receptor, so DHT has less effect on the follicle where it's applied. The idea is to slow the gradual shrinking of hair follicles in hereditary hair loss without affecting hormones throughout the body, as finasteride tablets do. In a 2019 lab study, the substance dampened androgen-driven signals about as well as finasteride in a cell test, and in cultured cells from scalp hair follicles it dampened an inflammatory signal better than another antiandrogen. That's cells in a dish, not hair on a head.
Who's behind it. Cosmo Pharmaceuticals. The trial registry lists its subsidiary Cassiopea as sponsor. The developer has previously referred to the hair loss solution as Breezula (with the code name CB-03-01), which is why many people search for that name. It's not certain a finished product will carry that name. The same active ingredient is already approved in the USA as a 1% cream for acne, but the solution being tested for hair loss is 5% and made for the scalp.
What the studies show. Two equally sized phase 3 studies, SCALP 1 and SCALP 2, enrolled 1,465 men over 18 at 51 centres in the USA, Germany and Poland. Participants used either clascoterone or a solution with no active ingredient for six months, without anyone knowing who got what, and then continued for another six months. In December 2025 the company announced that hair count in a defined area of the scalp was 5.39 times better than with the inactive solution in one study and 1.68 times better in the other. One study met its goal for how patients themselves rated their hair growth, and the other showed a trend in the same direction. Twelve-month data came in April 2026: those who stayed on clascoterone for the whole year had a 2.39 times better hair count than those switched to the inactive solution after six months.
How to read the figures. All the figures are relative. They say how much better the group did than the comparison group, not how many more hairs you'll get. We haven't found absolute hair counts published. The difference between the two studies is also large, 5.39 against 1.68. The figures come from the company's press releases and, as far as we can find, have not been published in a peer-reviewed journal.
Side effects and safety. The company states that side effects were about as common as with the inactive solution, and that little of the substance is absorbed into the body. Even so, the approved acne cream carries two warnings in the US prescribing information: the signalling axis between the brain and the adrenal glands (the HPA axis) can be suppressed during or after treatment, and some participants had raised potassium in the blood. The most common side effects of the cream were redness, itching and flaking in 7 to 12%. The hair solution is stronger and applied to a large area for years, so long-term data will be especially important.
What we don't know. Only men have been tested in phase 3. The drug hasn't been compared directly with finasteride or minoxidil, and we don't know what happens after more than twelve months. The company plans to seek approval in the USA in early 2027 and in Europe after that.
Clascoterone is not approved for hair loss in Norway, the EU or the USA as of October 2026. The acne cream is made and approved for facial skin, not the scalp. Don't use it for hair loss on your own.
Pyrilutamide (KX-826): what do the studies show?
What it is. Pyrilutamide is also an antiandrogen applied to the scalp, meant to block the androgen receptor locally. According to the manufacturer, the Chinese company Kintor, the substance is quickly broken down into inactive forms, so the effect stays in the skin.
The studies, in the order they came. The story is messy, and that's why the drug is discussed so much.
- USA, phase 2 (May 2023): 123 men with hair loss at Norwood stage III to V. The group using 0.5% twice daily had around 10 more hairs per square centimetre after 24 weeks compared with when they started. The company didn't give the placebo group's figures in its announcement, and the p-value it reported related to the change from baseline, not the difference from placebo.
- China, phase 3 (November 2023): 0.5% twice daily for 24 weeks. Hair increased from baseline, but the difference from placebo was not statistically significant. The company reported this itself to the Hong Kong Stock Exchange.
- China, long-term study (March 2025): an open-label study over 52 weeks where the main goal was side effects. The company states the goal was met and that no sexual side effects linked to the drug were seen.
- China, phase 3 (March 2026): 666 men at 26 centres for 24 weeks. With 1% twice daily, hair count rose by 15.33 hairs per square centimetre, against 4.68 with placebo. The difference, 10.65 hairs, was statistically significant. With 0.5% the difference was 9.78.
How to read the figures. All the results above are the company's own announcements. We haven't found any of the phase 3 studies published in a peer-reviewed journal. The latest study was done in Chinese men, and an earlier phase 3 at a lower strength missed its goal.
Side effects and safety. Kintor states that side effects were mostly mild and as common as with placebo, and that no serious side effects were linked to the drug. That's promising, but without published data nobody outside the company can check it.
What we don't know. Effect and safety over several years, effect in women outside China, and whether the drug will ever be submitted for approval in Europe. Kintor says it will seek approval in China.
Pyrilutamide is not approved for hair loss in any country as of October 2026. Products sold online under the name "KX-826" or "pyrilutamide" are not controlled medicines, and you don't know what they contain.
PP405: can it wake up dormant hair follicles?
What it is. PP405 is a small molecule applied to the scalp. It's being developed by Pelage Pharmaceuticals in Los Angeles, a company building on research from the University of California, Los Angeles (UCLA). The drug isn't meant to block hormones. Instead, the idea is to get the stem cells in the hair follicle to restart, so that a follicle that still exists but has stopped producing visible hair starts growing.
The research behind it. The basis is mouse studies from a research team at UCLA. In 2017 they showed in Nature Cell Biology that hair follicle stem cells produce a lot of lactic acid (lactate) when they wake up, and that the hair cycle sped up when they made the cells produce more of it, including by inhibiting a transporter in the cells' powerhouses. In 2021 the same group showed this also sped up the hair cycle in mice with hair loss caused by ageing, chemotherapy and stress. Pelage describes PP405 as a drug that targets "a metabolic switch" in the hair follicle. We can't confirm exactly which molecule PP405 is, so the link to the mouse studies is the company's own explanation of the idea.
What the studies show. In a phase 2a study with 78 participants aged 18 to 55, the drug was applied once daily for four weeks, and participants were followed for twelve weeks. The main goal was safety, and none of the substance was found in the blood. The company states that 31% of the men with the most hair loss had more than 20% denser hair after eight weeks, against none in the placebo group. That figure relates to a subgroup, effect was not what the study was primarily designed to measure, and the results are not peer-reviewed.
Next step. In October 2026, AWAKEN started: a phase 2/3 study with around 600 men with hair loss at Norwood stage IV or V in the USA and Canada. It runs for twelve months, is double-blind and has a placebo group. The trial registry estimates data collection for the main goal will be complete in December 2027. The company also says a study in women will start before the end of 2026.
Side effects and what we don't know. The only thing reported is four weeks of use in a small group. How the drug is tolerated over years, and whether the effect lasts when you stop, is unknown. Even if the idea works, it can only help follicles that still exist. Areas that have been completely bald for many years are unlikely to be what PP405 solves.
PP405 is an investigational drug and is not approved for hair loss anywhere as of October 2026. Pelage does not sell the drug. Whatever is sold online under similar code names is not made by the company and is not controlled.
GT20029: a drug that breaks down the hormone receptor
What it is. GT20029 comes from Kintor, the same company as pyrilutamide, but works in a different way. It's a so-called PROTAC: a molecule that attaches to the androgen receptor and at the same time to the cell's own system for clearing away proteins. The result is that the receptor is broken down rather than just blocked. A 2025 review article in the Journal of Medicinal Chemistry uses GT20029 and a similar drug, AH-001, as examples of such drugs being tested in clinical studies for hereditary hair loss.
What the studies show. A phase 2 study was published in the Journal of Dermatological Treatment in December 2025, and it's the only one of the new drugs here for which we've found a peer-reviewed study in people with hair loss. 180 Chinese men with hair loss at Norwood stage III to V received 0.5% or 1% once daily, twice a week, or placebo, for twelve weeks. Hair count rose in all four treatment groups. Two of them, 0.5% daily and 1% twice a week, were statistically better than placebo. The 1% twice-a-week group also had thicker hair shafts than the placebo group. The possibility that two applications a week could be enough is part of the reason for the interest.
Side effects and safety. Side effects were about equally common in all groups, and most were mild.
What we don't know. Twelve weeks is a short time in hair research. All participants were men in China, and several of the authors are employed by Kintor. The authors themselves write that more studies are needed, and a commentary in the same journal in 2026 raised questions about the method. Kintor has said the next step is phase 3.
GT20029 is not approved for hair loss anywhere as of October 2026, and there's no legal way to get hold of it outside a clinical study.
RU58841: why does a substance from the 1990s still keep turning up?
RU58841 is an antiandrogen developed to be applied to the skin. It was described in research in the early 1990s, and in a 1997 study it produced more hair growth in balding scalp from men that had been transplanted onto mice. Testing in humans was never completed, and nobody has ever had it approved as a medicine.
Even so, it's one of the most discussed substances on Reddit, because it's sold online as a "research chemical" with users' own recipes for use. In a 2026 anti-doping study, six healthy men had a single dose applied to the scalp, and the researchers found the substance in the blood. That weakens the claim that it only works locally. Read more in our review of RU58841.
RU58841 is not approved in any country, and the products sold are not of pharmaceutical quality. If you use it, tell your doctor and surgeon before a procedure.
Verteporfin: scar-free healing in the donor area?
Verteporfin is approved as a medicine for an eye disease, wet age-related macular degeneration. The interest from hair transplantation comes from the fact that the substance blocks a signal in cells, YAP, which helps determine whether a wound turns into a scar. Researchers at Stanford showed in 2021 that wounds in mice healed without scarring and with new hair follicles when the signal was blocked, and in 2025 they got similar results in pigs.
In humans there is so far no controlled study in hair transplantation. One patient is described in a case report, and a Danish study at Odense University Hospital is set to test the substance in wounds, but it isn't recruiting yet. The substance also makes tissue sensitive to light. Read the full review of verteporfin and the donor area.
Verteporfin is only approved for eye disease. Use on the scalp or donor area is experimental and off-label.
Hair cloning: how far has the research got?
Hair cloning means growing new hair follicles from the patient's own cells, so the donor area no longer limits how much hair can be moved. The American company Stemson Therapeutics announced in February 2024 that it had produced hair follicles from engineered cells in human skin transplanted onto mice. The company called it a step towards human trials but gave no date.
Two review articles from 2026 point to what stands in the way: it's hard to grow hair follicles at scale, they often don't develop fully, and the methods aren't standardised. We haven't found published results from trials in humans.
No clinic can offer hair cloning today. If you're offered it, ask for the studies it's based on.
Why do these drugs spread so fast on social media?
Because hope gets shared more than caveats. A before-and-after photo with a code name from a trial gets far more attention than the news that a study missed its goal. On Reddit, in groups like r/tressless, people share their own recipes with substances they've bought online. On TikTok and Instagram the same thing becomes short clips, often without a source. On X, company press releases get shared quickly, often with just the headline.
That's not surprising. Many people losing their hair have tried what's available and would love to hear that something better is just round the corner. But a code name in a video tells you nothing about what's in the bottle, how much you should use or what happens after a year. And the companies' own figures are designed to show off what went well.
Can you trust hair transplant posts on Instagram, TikTok and Snapchat?
Much of what you see about hair loss and hair transplants on social media is selected to show the best result, and some of it is advertising. That doesn't make the content worthless, but it means you have to read it differently from a study.
- Instagram: clinics, agents and patients post before-and-after photos of hair transplants, often under hashtags like #hairtransplant and #hårtransplantasjon. The photos usually show the best cases.
- TikTok: many people film the whole process, from a shaved head and scabs the day after the procedure to the result after a year. Tips about hair loss and new drugs spread quickly, often without a source.
- Snapchat: photos here are mostly shared privately, and filters can make hair look denser or move the hairline. That makes it hard to compare photos over time.
- YouTube and Reddit: longer videos and threads where people talk about their own experiences with clinics, medicines and trial drugs. Here you'll find both thorough accounts and pure guesswork.
- Facebook and X: groups for people who've been to the same clinic, and press releases about new drugs shared quickly, often with just the headline.
Is it advertising? In Norway, all marketing must be clearly recognisable as marketing, and hidden advertising is banned. Forbrukertilsynet (the Norwegian Consumer Authority) considers Instagram's own "Paid partnership" label not clear enough on its own, and recommends the words "reklame" (advertising) or "annonse" (advertisement). If you see a hair transplant presented as a personal story, it's worth checking whether it's labelled.
How to read a before-and-after photo. Look for the same lighting, the same angle and the same hair length in both photos. Wet hair, strong light from above and a short cut make thin hair look thinner, and hair fibres or filters can do the opposite. Ask how much time has passed and how many grafts were used. We've written more about this in the guide to hair transplant before-and-after photos and in the article on red flags at a hair clinic. If you're considering a clinic in Istanbul that you've seen on TikTok or Instagram, you can read about hair transplants in Turkey.
Social media content doesn't replace an assessment of your own hair. A result on someone else's head says little about what's possible for you, and a trial drug that seems to work in a video still hasn't finished testing.
Can you buy the new hair loss drugs online?
No, not legally, and not safely. Direktoratet for medisinske produkter (DMP, the Norwegian Medical Products Agency) states that medicines sent by post from abroad are not permitted, whether non-prescription or prescription, and that a Norwegian prescription does not give you the right to buy the equivalent from abroad. Tolletaten (Norwegian Customs) can stop such parcels and seize and destroy the contents.
On top of that, you don't know what you're getting. A powder or liquid sold as a "research chemical" is not made or controlled as a medicine. Content, strength and purity are unknown, and nobody follows you up if your skin reacts or something else goes wrong.
Should you wait for the new drugs before having a hair transplant?
That's a choice you make with a doctor or clinic, but don't wait for something that doesn't exist yet. Hereditary hair loss carries on while you wait. None of the drugs above has shown it can create new hair follicles where the old ones are completely gone, and that's exactly what a hair transplant solves by moving follicles from the back of the head. If one of them reaches the market, it will in all likelihood be an add-on to preserve the hair you have, the way finasteride and minoxidil are used today.
What is proven to work for hereditary hair loss today?
Finasteride and minoxidil. Both have many years of research behind them and are used both on their own and alongside a hair transplant. Finasteride requires a prescription. Topical minoxidil can be bought without a prescription at the pharmacy (in Norway the pack says minoksidil). Read more on the page about finasteride and dutasteride and the page about minoxidil for hair loss. If you've seen tretinoin and minoxidil on TikTok, it's covered in the article on the TikTok combination.
This article gives general information about research and trends and is not medical advice. We do not recommend using trial drugs outside clinical studies. Talk to a doctor before you start, change or stop any hair loss treatment.
Sources
- Kintor Pharmaceutical. Phase III KX-826 Tincture 1.0% For AGA Reached Primary Endpoint. Press release, 18 March 2026. en.kintor.com.cn
- Kintor Pharmaceutical. Results of KX-826 Phase III Clinical Trial for Treatment of Male AGA in China. Stock exchange announcement, Hong Kong Stock Exchange, 27 November 2023. hkexnews.hk
- GEN. Cosmo Pharma Eyes 2027 NDA for Baldness Candidate After Positive Phase III 12-Month Data. 21 April 2026. genengnews.com
- ClinicalTrials.gov. SCALP 1 (NCT05910450) and SCALP 2 (NCT05914805), clascoterone solution for male pattern hair loss. clinicaltrials.gov/study/NCT05910450
- Pelage Pharmaceuticals. First Patient Dosed in Phase 2/3 AWAKEN Trial of PP405. Press release, 14 October 2026. biospace.com. Trial registry: NCT07819435
- Dermatology Times. Pelage's PP405 Demonstrates Efficacy in Phase 2a Trial for Androgenetic Alopecia. 23 June 2025. dermatologytimes.com. Trial registry: NCT06393452
- Hu R, Wei A, Wu L, et al. Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study. Journal of Dermatological Treatment, 2025;36(1):2574304. PMID 41328006. pubmed.ncbi.nlm.nih.gov/41328006
- Agrawal A, Dreifus EM, Tosti A. Emerging pharmacotherapies for androgenetic alopecia. Expert Opinion on Pharmacotherapy, 2026;27(10):929-939. PMID 42290527. pubmed.ncbi.nlm.nih.gov/42290527
- Stemson Therapeutics. Stemson Therapeutics Announces Technological Breakthrough in New Hair Growth. Press release, 6 February 2024. biospace.com
- Direktoratet for medisinske produkter. Import av legemidler til personlig bruk ved forsendelse (import of medicines for personal use by post, updated 12.10.2026). dmp.no
- Rosette C, Rosette N, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro. Journal of Drugs in Dermatology, 2019;18(2):197-201. PMID 30811143. pubmed.ncbi.nlm.nih.gov/30811143
- Dermatology Times. Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results (reports Cosmo's press release of 3 December 2025). dermatologytimes.com
- U.S. Food and Drug Administration / DailyMed. WINLEVI (clascoterone) cream, prescribing information, warnings section. dailymed.nlm.nih.gov
- Kintor Pharmaceutical. Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US. 11 May 2023. en.kintor.com.cn
- Kintor Pharmaceutical. Long-Term Safety Phase III Clinical Trial of KX-826 for the Treatment of AGA Reached Primary Endpoint. 20 March 2025. en.kintor.com.cn
- Flores A, Schell J, Krall AS, et al. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nature Cell Biology, 2017;19(9):1017-1026. PMID 28812580. pubmed.ncbi.nlm.nih.gov/28812580
- Flores A, Choi S, Hsu YC, Lowry WE. Inhibition of pyruvate oxidation as a versatile stimulator of the hair cycle in models of alopecia. Experimental Dermatology, 2021;30(4):448-456. PMID 33739490. pubmed.ncbi.nlm.nih.gov/33739490
- UCLA Technology Development Group. GV Backs Hair Loss Biotech out of UCLA with PhII set for mid-2024. tdg.ucla.edu
- Pelage Pharmaceuticals. Our program. pelagepharma.com
- Gioiello L, Di Martino RMC, Pirali T. Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery. Journal of Medicinal Chemistry, 2025;68(22):23676-23689. PMID 41255358. pubmed.ncbi.nlm.nih.gov/41255358
- Tringali S. Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia. Journal of Dermatological Treatment, 2026;37(1):2616552. PMID 41537317. pubmed.ncbi.nlm.nih.gov/41537317
- De Brouwer B, Tételin C, Leroy T, Bonfils A, Van Neste D. A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp graft maintained on testosterone-conditioned nude mice. British Journal of Dermatology, 1997;137(5):699-702. PMID 9415227. pubmed.ncbi.nlm.nih.gov/9415227
- Okutan A, Krug O, Fußhöller G, Piper T, Thevis M. Investigation Into the Metabolism and Elimination Behavior of RU 58841, and Its Influence on the Steroid Profile in Humans. Biomedical Chromatography, 2026;40(10):e70602. PMID 42615108. pubmed.ncbi.nlm.nih.gov/42615108
- Mascharak S, Griffin M, Talbott HE, et al. Inhibiting mechanotransduction prevents scarring and yields regeneration in a large animal model. Science Translational Medicine, 2025;17(786). PMID 39970235. pubmed.ncbi.nlm.nih.gov/39970235
- Yao X, Ding R, Chuanjian Y, et al. Hair follicle organoids: advances in construction, applications, and translational challenges. Frontiers in Cell and Developmental Biology, 2026;14:1836905. PMID 42293765. pubmed.ncbi.nlm.nih.gov/42293765
- Paphawannasri P, Tawonsawatruk T, Phetfong J, Supokawej A. Stem cell-based approaches for alopecia: A narrative review of current and emerging treatment strategies. Cell Transplantation, 2026;35. PMID 42246281. pubmed.ncbi.nlm.nih.gov/42246281
- Forbrukertilsynet. Veileder for merking av reklame i sosiale medier (guidance on labelling advertising on social media, last updated 18.05.2026). forbrukertilsynet.no
If your hair loss has only just started, a procedure may not be the right step yet. The medical team at the clinic at the top of our ranking can look at your photos and tell you honestly whether to wait, start with treatment or consider more.
Goes to the clinic at the top of our ranking.